New biomarker predicts chemotherapy response in triple-negative breast cancer
Patients with triple-negative breast cancer have different treatment responses
Computational tools that predict treatment response historically overlook gene expression changes relative to the tumor microenvironment
New computational approach outperformed current methods for predicting chemotherapy response in patients with triple-negative breast cancer
Biomarker also directs some patients to alternative therapy and highlights population-specific...
Antibody-drug conjugate achieves high response rates as frontline treatment in aggressive, rare blood cancer
Phase II study evaluates treatment for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare, aggressive blood cancer
The...
Biomarkers predict patients with glioblastoma who will survive longer after treatment with cancer-targeting virus
Glioblastoma is a deadly brain cancer that suppresses the immune system and doesn’t respond well to available therapies
Researchers engineered...
First-in-human study finds novel immune cell therapy is safe and effective in advanced lymphoma
The novel cell therapy, called RB-1355, appears safe and well tolerated
RB-1355 offers unique advantages, such as being ready in about one week, not requiring lymphodepleting chemotherapy, and no requirement for a patient’s lymphoma to express actionable mutations
Early signs of clinical efficacy were observed in difficult-to-treat, relapsed or refractory lymphomas
The treatment triggers positive and favorable immune changes inside the...
Americans prefer to screen for cervical cancer in-clinic vs. at home
More than 60% of American women prefer to get their cervical cancer screening in a clinic versus at home with a self-sampling kit, study finds...
Study shows strong evidence for effectiveness of metastasis-directed radiation therapy in prostate cancer
Metastasis-directed therapy (MDT) significantly improved progression-free survival and later endpoints
Data indicate statistically significant...